4/13
07:30 am
pvla
Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors
Low
Report
Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors
4/7
07:30 am
pvla
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
Low
Report
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
4/1
11:39 pm
pvla
Palvella's Phase III Success And Fast Track Status Test Current Valuation [Yahoo! Finance]
Low
Report
Palvella's Phase III Success And Fast Track Status Test Current Valuation [Yahoo! Finance]
3/31
05:23 pm
pvla
Palvella Therapeutics (PVLA) had its price target raised by Chardan Capital from $210.00 to $240.00. They now have a "buy" rating on the stock.
Medium
Report
Palvella Therapeutics (PVLA) had its price target raised by Chardan Capital from $210.00 to $240.00. They now have a "buy" rating on the stock.
3/31
03:22 pm
pvla
Palvella Therapeutics Inc (PVLA) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
Low
Report
Palvella Therapeutics Inc (PVLA) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
3/31
07:39 am
pvla
Palvella Therapeutics GAAP EPS of -$3.71 misses by $0.19 [Seeking Alpha]
High
Report
Palvella Therapeutics GAAP EPS of -$3.71 misses by $0.19 [Seeking Alpha]
3/31
07:30 am
pvla
Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
High
Report
Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
3/30
08:05 am
pvla
Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations [Yahoo! Finance]
Low
Report
Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations [Yahoo! Finance]
3/30
07:30 am
pvla
Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations
Low
Report
Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations
3/27
10:30 am
pvla
Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting
Medium
Report
Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting
3/25
06:52 pm
pvla
Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) Signal [Yahoo! Finance]
Low
Report
Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) Signal [Yahoo! Finance]
3/24
04:27 pm
pvla
Director Buys $500,000 Worth of Palvella Therapeutics Shares After Phase 3 Win [Yahoo! Finance]
Medium
Report
Director Buys $500,000 Worth of Palvella Therapeutics Shares After Phase 3 Win [Yahoo! Finance]
3/24
11:48 am
pvla
Palvella Therapeutics (PVLA) had its price target raised by HC Wainwright from $255.00 to $270.00. They now have a "buy" rating on the stock.
Low
Report
Palvella Therapeutics (PVLA) had its price target raised by HC Wainwright from $255.00 to $270.00. They now have a "buy" rating on the stock.
3/24
07:53 am
pvla
Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026 [TheStreet.com]
Low
Report
Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026 [TheStreet.com]
3/24
07:30 am
pvla
Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026
Low
Report
Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026
3/23
07:40 am
pvla
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services [Yahoo! Finance]
Low
Report
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services [Yahoo! Finance]
3/23
07:30 am
pvla
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
Low
Report
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
3/17
12:32 am
pvla
Palvella Therapeutics: A Potential First-In-Class Therapy In A Rare Dermatology Market [Seeking Alpha]
Medium
Report
Palvella Therapeutics: A Potential First-In-Class Therapy In A Rare Dermatology Market [Seeking Alpha]
3/16
03:21 pm
pvla
Palvella Therapeutics (PVLA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $210.00 price target on the stock.
Low
Report
Palvella Therapeutics (PVLA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $210.00 price target on the stock.
3/16
07:41 am
pvla
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin [Yahoo! Finance]
Low
Report
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin [Yahoo! Finance]
3/16
07:30 am
pvla
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin
Medium
Report
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin
3/10
08:04 am
pvla
Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations [Yahoo! Finance]
Low
Report
Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations [Yahoo! Finance]
3/10
07:30 am
pvla
Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations
Medium
Report
Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations
3/2
07:30 am
pvla
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Low
Report
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
2/25
07:57 pm
pvla
Palvella Therapeutics Announces Pricing of Upsized Public Offering
High
Report
Palvella Therapeutics Announces Pricing of Upsized Public Offering